NMG
CUE icon

New Millennium Group’s Cue Biopharma CUE Stock Holding History

New Millennium Group’s Portfolio CUE Stock Details CUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$1.76K Buy
+192
New +$3.53K ﹤0.01% 303

Other funds holding CUE

BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
GWMR
GC Wealth Management RIA Cambridge, Massachusetts $1.73B AUM 16.14% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
RSWM
Robertson Stephens Wealth Management San Francisco, California $3.57B AUM 28.36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.68B AUM 21.72% 1-Year Est. Return
AWM
Angeles Wealth Management Santa Monica, California $1.84B AUM 19.34% 1-Year Est. Return

New Millennium Group's CUE Position: Q4 2025 in Review

New Millennium Group opened a new position in Cue Biopharma (CUE) in Q4 2025: 192 shares worth $1.76K. The stake represents ﹤0.01% of the portfolio and ranks #303 among its holdings.

47 funds tracked by Wall St. Rank hold CUE as of Q4 2025.

  • New Millennium Group held 192 shares of Cue Biopharma worth $1.76K as of Q4 2025.
  • Cue Biopharma was a new New Millennium Group position in Q4 2025.
  • Cue Biopharma made up ﹤0.01% of New Millennium Group's portfolio in Q4 2025, its #303 holding.
  • 47 funds tracked by Wall St. Rank held Cue Biopharma as of Q4 2025.

Based on New Millennium Group's 13F filing for Q4 2025, filed 6 Feb 2026.